CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria. / Neisinger, Sophia; Sousa Pinto, Bernardo; Ramanauskaite, Aiste; Bousquet, Jean; Weller, Karsten; Metz, Martin; Magerl, Markus; Kocatürk, Emek; Cherrez-Ojeda, Ivan; Gimenez-Arnau, Ana M.; Parisi, Claudio Alberto S.; Altrichter, Sabine; Ensina, Luis Felipe; Bouillet, Laurence; Asero, Riccardo; Gonçalo, Margarida; Guillet, Carole; Rutkowski, Krzysztof; Bernstein, Jonathan A.; Hardin, Hannah; Godse, Kiran; Brzoza, Zenon; Sousa, Jose Ignacio Larco; Thomsen, Simon Francis; van Doorn, Martijn; Hide, Michihiro; Ye, Young Min; Vanderse, Staffan; Lapiņa, Lāsma; Peter, Jonny; Zhao, Zuotao; Han, Lianyi; Nasr, Iman; Rockmann-Helmbach, Heike; Sørensen, Jennifer Astrup; Kara, Rabia Öztaş; Kurjāne, Natalja; Kurchenko, Andrii I.; Kaidashev, Igor; Tsaryk, Vladyslav; Stepanenko, Roman; Maurer, Marcus.

I: Clinical and Translational Allergy, Bind 14, Nr. 1, e12328, 2024.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Neisinger, S, Sousa Pinto, B, Ramanauskaite, A, Bousquet, J, Weller, K, Metz, M, Magerl, M, Kocatürk, E, Cherrez-Ojeda, I, Gimenez-Arnau, AM, Parisi, CAS, Altrichter, S, Ensina, LF, Bouillet, L, Asero, R, Gonçalo, M, Guillet, C, Rutkowski, K, Bernstein, JA, Hardin, H, Godse, K, Brzoza, Z, Sousa, JIL, Thomsen, SF, van Doorn, M, Hide, M, Ye, YM, Vanderse, S, Lapiņa, L, Peter, J, Zhao, Z, Han, L, Nasr, I, Rockmann-Helmbach, H, Sørensen, JA, Kara, RÖ, Kurjāne, N, Kurchenko, AI, Kaidashev, I, Tsaryk, V, Stepanenko, R & Maurer, M 2024, 'CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria', Clinical and Translational Allergy, bind 14, nr. 1, e12328. https://doi.org/10.1002/clt2.12328

APA

Neisinger, S., Sousa Pinto, B., Ramanauskaite, A., Bousquet, J., Weller, K., Metz, M., Magerl, M., Kocatürk, E., Cherrez-Ojeda, I., Gimenez-Arnau, A. M., Parisi, C. A. S., Altrichter, S., Ensina, L. F., Bouillet, L., Asero, R., Gonçalo, M., Guillet, C., Rutkowski, K., Bernstein, J. A., ... Maurer, M. (2024). CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria. Clinical and Translational Allergy, 14(1), [e12328]. https://doi.org/10.1002/clt2.12328

Vancouver

Neisinger S, Sousa Pinto B, Ramanauskaite A, Bousquet J, Weller K, Metz M o.a. CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria. Clinical and Translational Allergy. 2024;14(1). e12328. https://doi.org/10.1002/clt2.12328

Author

Neisinger, Sophia ; Sousa Pinto, Bernardo ; Ramanauskaite, Aiste ; Bousquet, Jean ; Weller, Karsten ; Metz, Martin ; Magerl, Markus ; Kocatürk, Emek ; Cherrez-Ojeda, Ivan ; Gimenez-Arnau, Ana M. ; Parisi, Claudio Alberto S. ; Altrichter, Sabine ; Ensina, Luis Felipe ; Bouillet, Laurence ; Asero, Riccardo ; Gonçalo, Margarida ; Guillet, Carole ; Rutkowski, Krzysztof ; Bernstein, Jonathan A. ; Hardin, Hannah ; Godse, Kiran ; Brzoza, Zenon ; Sousa, Jose Ignacio Larco ; Thomsen, Simon Francis ; van Doorn, Martijn ; Hide, Michihiro ; Ye, Young Min ; Vanderse, Staffan ; Lapiņa, Lāsma ; Peter, Jonny ; Zhao, Zuotao ; Han, Lianyi ; Nasr, Iman ; Rockmann-Helmbach, Heike ; Sørensen, Jennifer Astrup ; Kara, Rabia Öztaş ; Kurjāne, Natalja ; Kurchenko, Andrii I. ; Kaidashev, Igor ; Tsaryk, Vladyslav ; Stepanenko, Roman ; Maurer, Marcus. / CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria. I: Clinical and Translational Allergy. 2024 ; Bind 14, Nr. 1.

Bibtex

@article{fdbd88307617417588cc4d455c109b00,
title = "CRUSE{\textregistered}—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria",
abstract = "Background: Chronic spontaneous urticaria (CSU) is unpredictable and can severely impair patients' quality of life. Patients with CSU need a convenient, user-friendly platform to complete patient-reported outcome measures (PROMs) on their mobile devices. CRUSE{\textregistered}, the Chronic Urticaria Self Evaluation app, aims to address this unmet need. Methods: CRUSE{\textregistered} was developed by an international steering committee of urticaria specialists. Priorities for the app based on recent findings in CSU were defined to allow patients to track and record their symptoms and medication use over time and send photographs. The CRUSE{\textregistered} app collects patient data such as age, sex, disease onset, triggers, medication, and CSU characteristics that can be sent securely to physicians, providing real-time insights. Additionally, CRUSE{\textregistered} contains PROMs to assess disease activity and control, which are individualised to patient profiles and clinical manifestations. Results: CRUSE{\textregistered} was launched in Germany in March 2022 and is now available for free in 17 countries. It is adapted to the local language and displays a country-specific list of available urticaria medications. English and Ukrainian versions are available worldwide. From July 2022 to June 2023, 25,710 observations were documented by 2540 users; 72.7% were females, with a mean age of 39.6 years. At baseline, 93.7% and 51.3% of users had wheals and angioedema, respectively. Second-generation antihistamines were used in 74.0% of days. Conclusions: The initial data from CRUSE{\textregistered} show the wide use and utility of effectively tracking patients' disease activity and control, paving the way for personalised CSU management.",
keywords = "chronic urticaria self evaluation (CRUSE) app, digital tools, mHealth apps, patient-reported outcome measures, wheals and angioedema",
author = "Sophia Neisinger and {Sousa Pinto}, Bernardo and Aiste Ramanauskaite and Jean Bousquet and Karsten Weller and Martin Metz and Markus Magerl and Emek Kocat{\"u}rk and Ivan Cherrez-Ojeda and Gimenez-Arnau, {Ana M.} and Parisi, {Claudio Alberto S.} and Sabine Altrichter and Ensina, {Luis Felipe} and Laurence Bouillet and Riccardo Asero and Margarida Gon{\c c}alo and Carole Guillet and Krzysztof Rutkowski and Bernstein, {Jonathan A.} and Hannah Hardin and Kiran Godse and Zenon Brzoza and Sousa, {Jose Ignacio Larco} and Thomsen, {Simon Francis} and {van Doorn}, Martijn and Michihiro Hide and Ye, {Young Min} and Staffan Vanderse and Lāsma Lapiņa and Jonny Peter and Zuotao Zhao and Lianyi Han and Iman Nasr and Heike Rockmann-Helmbach and S{\o}rensen, {Jennifer Astrup} and Kara, {Rabia {\"O}zta{\c s}} and Natalja Kurjāne and Kurchenko, {Andrii I.} and Igor Kaidashev and Vladyslav Tsaryk and Roman Stepanenko and Marcus Maurer",
note = "Publisher Copyright: {\textcopyright} 2024 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.",
year = "2024",
doi = "10.1002/clt2.12328",
language = "English",
volume = "14",
journal = "Clinical and Translational Allergy",
issn = "2045-7022",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

AU - Neisinger, Sophia

AU - Sousa Pinto, Bernardo

AU - Ramanauskaite, Aiste

AU - Bousquet, Jean

AU - Weller, Karsten

AU - Metz, Martin

AU - Magerl, Markus

AU - Kocatürk, Emek

AU - Cherrez-Ojeda, Ivan

AU - Gimenez-Arnau, Ana M.

AU - Parisi, Claudio Alberto S.

AU - Altrichter, Sabine

AU - Ensina, Luis Felipe

AU - Bouillet, Laurence

AU - Asero, Riccardo

AU - Gonçalo, Margarida

AU - Guillet, Carole

AU - Rutkowski, Krzysztof

AU - Bernstein, Jonathan A.

AU - Hardin, Hannah

AU - Godse, Kiran

AU - Brzoza, Zenon

AU - Sousa, Jose Ignacio Larco

AU - Thomsen, Simon Francis

AU - van Doorn, Martijn

AU - Hide, Michihiro

AU - Ye, Young Min

AU - Vanderse, Staffan

AU - Lapiņa, Lāsma

AU - Peter, Jonny

AU - Zhao, Zuotao

AU - Han, Lianyi

AU - Nasr, Iman

AU - Rockmann-Helmbach, Heike

AU - Sørensen, Jennifer Astrup

AU - Kara, Rabia Öztaş

AU - Kurjāne, Natalja

AU - Kurchenko, Andrii I.

AU - Kaidashev, Igor

AU - Tsaryk, Vladyslav

AU - Stepanenko, Roman

AU - Maurer, Marcus

N1 - Publisher Copyright: © 2024 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.

PY - 2024

Y1 - 2024

N2 - Background: Chronic spontaneous urticaria (CSU) is unpredictable and can severely impair patients' quality of life. Patients with CSU need a convenient, user-friendly platform to complete patient-reported outcome measures (PROMs) on their mobile devices. CRUSE®, the Chronic Urticaria Self Evaluation app, aims to address this unmet need. Methods: CRUSE® was developed by an international steering committee of urticaria specialists. Priorities for the app based on recent findings in CSU were defined to allow patients to track and record their symptoms and medication use over time and send photographs. The CRUSE® app collects patient data such as age, sex, disease onset, triggers, medication, and CSU characteristics that can be sent securely to physicians, providing real-time insights. Additionally, CRUSE® contains PROMs to assess disease activity and control, which are individualised to patient profiles and clinical manifestations. Results: CRUSE® was launched in Germany in March 2022 and is now available for free in 17 countries. It is adapted to the local language and displays a country-specific list of available urticaria medications. English and Ukrainian versions are available worldwide. From July 2022 to June 2023, 25,710 observations were documented by 2540 users; 72.7% were females, with a mean age of 39.6 years. At baseline, 93.7% and 51.3% of users had wheals and angioedema, respectively. Second-generation antihistamines were used in 74.0% of days. Conclusions: The initial data from CRUSE® show the wide use and utility of effectively tracking patients' disease activity and control, paving the way for personalised CSU management.

AB - Background: Chronic spontaneous urticaria (CSU) is unpredictable and can severely impair patients' quality of life. Patients with CSU need a convenient, user-friendly platform to complete patient-reported outcome measures (PROMs) on their mobile devices. CRUSE®, the Chronic Urticaria Self Evaluation app, aims to address this unmet need. Methods: CRUSE® was developed by an international steering committee of urticaria specialists. Priorities for the app based on recent findings in CSU were defined to allow patients to track and record their symptoms and medication use over time and send photographs. The CRUSE® app collects patient data such as age, sex, disease onset, triggers, medication, and CSU characteristics that can be sent securely to physicians, providing real-time insights. Additionally, CRUSE® contains PROMs to assess disease activity and control, which are individualised to patient profiles and clinical manifestations. Results: CRUSE® was launched in Germany in March 2022 and is now available for free in 17 countries. It is adapted to the local language and displays a country-specific list of available urticaria medications. English and Ukrainian versions are available worldwide. From July 2022 to June 2023, 25,710 observations were documented by 2540 users; 72.7% were females, with a mean age of 39.6 years. At baseline, 93.7% and 51.3% of users had wheals and angioedema, respectively. Second-generation antihistamines were used in 74.0% of days. Conclusions: The initial data from CRUSE® show the wide use and utility of effectively tracking patients' disease activity and control, paving the way for personalised CSU management.

KW - chronic urticaria self evaluation (CRUSE) app

KW - digital tools

KW - mHealth apps

KW - patient-reported outcome measures

KW - wheals and angioedema

UR - http://www.scopus.com/inward/record.url?scp=85181927659&partnerID=8YFLogxK

U2 - 10.1002/clt2.12328

DO - 10.1002/clt2.12328

M3 - Journal article

C2 - 38282190

AN - SCOPUS:85181927659

VL - 14

JO - Clinical and Translational Allergy

JF - Clinical and Translational Allergy

SN - 2045-7022

IS - 1

M1 - e12328

ER -

ID: 381508467